Drug Profile
Prostate cancer therapy - Debiopharm
Alternative Names: E2 agonist/GnRH agonist - Debiopharm; Estrogen agonist/gonadotrophin releasing hormone agonist - Debiopharm; GnRH agonist/E2 agonist - Debiopharm; Gonadotrophin releasing hormone agonist/estrogen agonist - Debiopharm; TRIO; TRIO - DebiopharmLatest Information Update: 29 Oct 2021
Price :
$50
*
At a glance
- Originator Debiopharm
- Class Hormones
- Mechanism of Action Estrogen receptor agonists; Gonadotropin releasing hormone stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Prostate cancer
Most Recent Events
- 05 Sep 2005 Phase-I/II clinical trials in Prostate cancer in Europe (unspecified route)